Drug intelligence / Profile preview

split-virion pandemic influenza vaccine (H5N1)

Development stage: Phase 2
Lead developer: Sinovac Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The split-virion pandemic influenza vaccine (H5N1) is a vaccine developed by Sinovac Biotech Co., Ltd. It is designed to provide immunity against the H5N1 strain of influenza A virus. This vaccine is a split-virion type, meaning it contains inactivated influenza virus particles that have been treated with a detergent to break them apart, exposing the internal viral proteins. It has been evaluated in clinical trials for its safety and immunogenicity.

Brand names: Panflu
Other names: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Beyond the preview

Go deeper on split-virion pandemic influenza vaccine (H5N1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on split-virion pandemic influenza vaccine (H5N1).

Explore the full profile